Passerini, Carlo Gambacorti and Farina, Francesca and Stasia, Alessandra and Redaelli, Sara and Ceccon, Monica and Mologni, Luca and Messa, Cristina and Guerra, Luca and Giudici, Giovanni and Sala, Elena and Mussolin, Lara and Deeren, Dries and King, Michael H. and Steurer, Michael and Ordemann, Rainer and Cohen, Amos M. and Grube, Matthias and Bernard, Lea and Chiriano, Gianpaolo and Antolini, Laura and Piazza, Rocco (2014) Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106 (2): djt378. ISSN 0027-8874, 1460-2105
Full text not available from this repository. (Request a copy)Abstract
Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were resistant/refractory to cytotoxic therapy. The overall response rate was 10 of 11 (90.9%; 95% confidence interval [CI] = 58.7% to 99.8%). Disease status at the latest follow-up is as follows: four patients are in complete response (CR) (months >21, >30, >35, >40) under continuous crizotinib administration; 4 patients had progression of disease (months 1, 2, 2, 2); 1 patient obtained CR on crizotinib, received an allogeneic bone marrow transplant, and is in CR; 2 patients (treated before and/or after allogeneic bone marrow transplant) obtained and are still in CR but they have stopped crizotinib. Overall and progression-free survival rates at 2 years are 72.7% (95% CI = 39.1% to 94.0%) and 63.7% (95% CI = 30.8% to 89.1%), respectively. ALK mutations conferring resistance to crizotinib in vitro could be identified in relapsed patients. Crizotinib exerted a potent antitumor activity with durable responses in advanced, heavily pretreated ALK+ lymphoma patients, with a benign safety profile.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | LARGE-CELL LYMPHOMA; ALK; TRANSLOCATION; DISEASE; CANCER; ALCL; NPM; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Nov 2019 13:36 |
| Last Modified: | 27 Nov 2019 13:36 |
| URI: | https://pred.uni-regensburg.de/id/eprint/10705 |
Actions (login required)
 |
View Item |
